|Awarded On||May 18, 2016|
|Title||Salarius Pharmaceuticals - Developing epigenetic drugs that treat Rare Pediatric Cancers|
|Program||Product Development Research|
|Award Mechanism||New Company Product Development Award|
|Institution/Organization||Salarius Pharmaceuticals LLC|
|Principal Investigator/Program Director||David Arthur|
|Cancer Sites||Breast, Leukemia, Prostate, Sarcoma|
Salarius specializes in developing novel drugs for rare pediatric cancers and other cancers by focusing on treatments that interrupt the final steps of the signaling cascade. Our first drug, SP-2577, targets the Lysine Specific Histone Demethylase 1 pathway (LSD1), a cellular control protein that’s overactive in a range of cancers. Salarius has developed a first-in-class highly specific LSD1 inhibitor that we will test in Ewing’s Sarcoma and other undifferentiated sarcomas, in addition to late stage prostate cancer.
We plan to file an IND in early 2016 and initiate phase 1 clinical studies in Ewing’s and prostate cancer in June 2016. Ewing’s is a rare devastating pediatric, adolescent...